Compare Charles River Laboratories Intl. Inc (CRL) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Sea Limited — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while Sea Limited trades at $108.8 (market cap $66.94B). The key difference: Sea Limited is far larger — about 6× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals.
| CRL | SE | |
|---|---|---|
Market Cap | $11.14B | $66.94B |
Sector | Health | Media |
52-Week High | $233.60 | $196.50 |
52-Week Low | $145.57 | $78.16 |
Enterprise Value | $14.00B | $59.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
SE trades at $110.66, down 0.43% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth, reaching $22.94B in 2025, and improving profitability with a net income margin of 6.36%. Recent earnings beat expectations in Q1 2026, but insider sales have drawn media attention. Cash flow turned positive in 2025 at $2.34B, reflecting operational strength.
Outlook remains positive with a consensus price target of $131, implying 18% upside. Risks include competitive pressures in Southeast Asia and execution on growth investments. Analyst sentiment is strongly bullish with 70% buy ratings, though high valuation multiples and recent insider selling warrant caution for near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
